Actemra Looks Promising in Scleroderma
Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study by Christopher P. Denton, MBBS, of University College Londo.
At 24 weeks, a numerically favorable response was seen on modified Rodnan skin scores and lung fibrosis among patients randomized to tocilizumab compared with those receiving placebo. The study is now continuing with a phase III trial that includes a greater number of patients.
news & events
The Swedish member of FESCA got a second place award in Sweden.
Study on the impact on various diets that might impact symptoms in Scleroderma.
Article by doctor Susana Oliveira, graduated Hospital Assistant and Systemic Sclerosis Consulting Coordinator at the Professor Doutor Fernando Fonseca Hospital